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Efficacy of esmolol as a myocardial protective agent during
continuous retrograde blood cardioplegia
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Objective: Esmolol, an ultra-short-acting -blocker, is known to attenuate myocar-
dial ischemia-reperfusion injury. The aim of this study was to compare the effects
of esmolol and potassium on myocardial metabolism during continuous normother-
mic retrograde blood cardioplegia.
Methods: Forty-one patients operated on for isolated aortic valve stenosis were
randomly assigned to continuous coronary infusion with either potassium or esmolol
during cardiopulmonary bypass. Myocardial metabolism was assessed by measuring
the transmyocardial gradient of oxygen content indexed to left ventricular mass of
glucose, lactate, and nitric oxide. To do so, blood samples were simultaneously
withdrawn upstream (in the cardioplegia line) and downstream of the myocardium
(in the left coronary ostium) 10 and 30 minutes after aortic crossclamping.
Results: Although the cardioplegia flow rate and pressure were similar, esmolol
markedly reduced the transmyocardial gradient of oxygen content indexed to left
ventricular mass compared with potassium: 13 6 vs 20 6 mL of oxygen per liter
of blood per 100 g of myocardium, respectively, at 10 minutes and 16  8 vs 24 
8 mL of oxygen per liter of blood per 100 g of myocardium, respectively, at 30
minutes (P  .009). Coronary glucose and lactate transmyocardial gradients were
similar in both groups, indicating adequate myocardial perfusion in all patients at all
times. In addition, during retrograde cardioplegia, esmolol showed a lower nitric
oxide release compared with that caused by potassium (39  49 mol  L1 for
potassium vs 14  8 mol  L1 for esmolol at 10 minutes and 39  47 mol 
L1 for potassium vs 6  8 mol  L1 for esmolol at 30 minutes, P  .05).
However, hemodynamic parameters and plasma troponin I levels remained un-
changed postoperatively between the 2 types of cardioplegia.
Conclusion: Esmolol provides potent myocardial protection in hypertrophied hearts,
at least in part, by reducing myocardial oxygen metabolism.
Cardioplegia-induced cardiac arrest is routinely used to providemyocardial protection, as well as a flaccid heart, during cardiacoperations. This is mostly achieved by using hyperkalemic cardio-plegia solution1,2; however, hyperkalemia has many adverse ef-fects.3-5 Patients who cannot eliminate the large amount of potas-sium administered during cardiopulmonary bypass (CPB) might
present a persistent increase of myocardial intracellular calcium concentration that
might ultimately impair contraction-relaxation of cardiac cells,5 induce longer
periods of bypass, and require pharmacologic or mechanical inotropic support.
Animal and human6,7 studies suggest that, as an alternative approach to hyperkale-
mic cardioplegic arrest, myocardial protection can be achieved with the use of the
ultra-short-acting -receptor blocker esmolol.8-10 Indeed, -receptor blockers might
reduce the extent of myocardial cell injury11-13 and reduce myocardial oxygen
From the Service de Chirurgie Cardiaque,
Centre Cardiologique du Nord, Saint-De-
nis, France; De´partement d’Anesthe´sie-Re´-
animation, Service de Biochimie et de Bi-
ologie Mole´culaire, CR Claude Bernard
“Pathologie Expe´rimentale et Communica-
tions Cellulaires,” Institut Fe´de´ratif de Re-
cherche, Hoˆpital Lariboisie`re, Paris,
France.
Read at the Eighty-second Annual Meeting
of The American Association for Thoracic
Surgery, Washington, DC, May 5-8, 2002.
Received for publication May 29, 2002;
revisions requested July 8, 2002; revisions
received July 22, 2002; accepted for publi-
cation Aug 14, 2002.
Address for reprints: Alexandre Mebazaa,
MD, PhD (E-mail: alexandre.mebazaa@
lrb.ap-hop-paris.fr) or Marcio Scorsin, MD,
PhD (E-mail: mscorsin@hotmail.com),
De´partement d’Anesthe´sie-Re´animation-
SMUR, Hoˆpital Lariboisie`re, 2 rue Am-
broise-Pare´, 75475 Paris Cedex 10, France.
J Thorac Cardiovasc Surg 2003;125:1022-9
Copyright © 2003 by The American Asso-
ciation for Thoracic Surgery
0022-5223/2003 $30.000
doi:10.1067/mtc.2003.175
Scorsin, Lessana, Mebazaa (left to right)
Cardiopulmonary Support and Physiology Scorsin et al
1022 The Journal of Thoracic and Cardiovascular Surgery ● May 2003
CSP
consumption by means of better oxygen use.14,15 The latter,
however, might be overcome by the persistence of a mini-
mal myocardial contraction when using esmolol during
aortic crossclamping.
Thus, the main objective of this study was to assess, in
patients operated on for aortic valve replacement with hy-
pertrophied left ventricles, whether esmolol can be as effi-
cient as potassium in protecting the myocardium during
continuous retrograde blood cardioplegia. Myocardial hy-
pertrophy was chosen because of its widely known de-
creased tolerance to ischemia during cardiac surgery. To do
so, we compared effects of esmolol and potassium on pre-
operative and postoperative hemodynamic and biologic pa-
rameters and on myocardial metabolic function, including
myocardial oxygen, glucose, and lactate use and myocardial
nitric oxide (NO) production during the aortic crossclamp-
ing period.
Methods
Patients
Forty-three patients with isolated aortic stenosis free from signif-
icant coronary artery lesions and scheduled for elective surgery
were admitted into the study. The study was approved by the
Ethics Committee of Hoˆpital Saint-Louis (Paris, France), and
written informed consent was obtained from each patient in the
preoperative period after a detailed explanation of the study’s
purpose by one of the investigators. Patients were randomly as-
signed to receive either the cardioselective -receptor blocker
esmolol (half-life of 9 minutes16; Baxter International, Inc, Deer-
field, Ill) or potassium during aortic crossclamping. Prerandom-
ization exclusion criteria were preoperative -blocker treatment
and a history of severe asthma. After randomization, 2 patients
from the potassium group were excluded because the coronary
sinus could not be cannulated for retroperfusion. Thus, 23 patients
were assigned to the esmolol group, and 18 patients were assigned
to the potassium group. Preoperative patient data are shown in
Table 1.
Operative Technique for Continuous Retrograde
Blood Cardioplegia
All patients were operated on for isolated aortic valve replacement
through a median sternotomy, and CPB was set up according to the
standard procedure between the ascending aorta for arterial inflow
and in the right atrium by using a 2-stage cannula for venous
return. A vent was placed in the left ventricular (LV) cavity
through the right superior pulmonary vein. CPB was conducted
during normothermia (perfusion temperature was maintained at
37°C), with a theoretical flow of 2.5 L  min1  m2
In addition to aortic crossclamping, initial antegrade flow of
cardioplegic solution was started in the aortic root through a line
originating from the arterial part of the oxygenator, with potassium
or esmolol diluted in normoxic blood (oxygen saturation of97%,
with PaO2 ranging from 90-120 mm Hg and blood flow of 0.3 L 
min1). Potassium (0.2 g  mL1) was administered at a total
dose of approximatively 1.2 g in the potassium group, whereas
esmolol (50 mg  mL1) was administered at a total dose of 250
to 300 mg in the esmolol group, both administered over 2 to 3
minutes in the cardioplega line. Although the heart was consis-
tently arrested in the potassium group without apparent contrac-
tion, it remained beating in the esmolol group at a rate of less than
30 beats/min with minimal myocardial contraction during aortic
crossclamping. For clarity, we will, however, use the term “car-
dioplegia” for both agents. After induction of cardioplegia in the
potassium group or minimal myocardial contraction in the esmolol
group (consistently 3 minutes for both solutions), antegrade
perfusion was stopped and relayed by means of retrograde contin-
uous myocardial perfusion through a self-inflating double-lumen
balloon cannula (DLP, Grand Rapids, Mich) placed by means of a
transright atrial blind cannulation of the coronary sinus. The myo-
cardial perfusion flow rate was kept constant at approximately 0.25
L  min1 to maintain a coronary sinus pressure of between 30
and 40 mm Hg. Cardioplegia was therefore maintained with a dose
of 4 to 6 g  h1 of potassium to obtain a final potassium
concentration of 12 mmol  L1 in the cardioplegia line in the
potassium group. Minimal myocardial contraction in the esmolol
group was maintained with a dose of 600 mg  h1, which was
reduced to 300 to 400 mg  h1 if the heart rate decreased to less
than 30 beats/min. Magnesium was also administered to all pa-
tients at a dose of 125 mL  h1 of 10% MgSO4.
Measurements
Hemodynamic parameters. Transesophageal echocardiogra-
phy was performed 1 day before and 5 days after the surgical
procedure to assess LV ejection fraction. Penn-cube LV mass was
measured, as previously described17:
1.04 ([IVST  LVID  PWT]3  LVID)3  13.6 g
where IVST is defined as interventricular septal thickness, LVID is
defined as LV internal dimension, and PWT is defined as posterior
wall thickness. All values are measured during end-diastole, and
the results were then indexed to body surface area. After obtain-
ment of general anesthesia and tracheal intubation, a Swan-Ganz
catheter (Edwards Lifesciences, Irvine, Calif) was introduced into
the pulmonary artery to record baseline hemodynamics before
sternotomy: mean pulmonary arterial pressure, cardiac index, and
mixed pulmonary artery oxygen saturation. Data were also re-
TABLE 1. Comparison of preoperative and intraoperative
parameters
K group ES group
Preoperative parameters
Age (y) 68 11 70 11
LV mass index (g  m2) 197 57 176 48
Preoperative LVEF (%) 59 13 65 12
Transaortic mean gradient* (mm Hg) 58 12 56 13
Preoperative Hb (g/dL) 13.6 2.2 13.2 1.6
Intraoperative parameters
Aortic crossclamping time (min) 58 10 54 11
CPB time (min) 79 9 80 13
No difference was observed between the 2 groups. K, Potassium; ES,
esmolol; LV mass index, LV mass/body surface area; LVEF, LV ejection
fraction; Hb, hemoglobin.
*Determined by means of 2-dimensional echocardiography.
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corded 4 hours after the end of the operation. All measurements
were made at a fraction of inspired oxygen of 0.5. The need for
catecholamines after CPB was also recorded.
Metabolic parameters. Blood samples were taken to measure
plasma lactate, troponin I, and creatinine levels before sternotomy
and at 4 hours after the operation. The plasma troponin I level was
also measured 24 hours after the operation. Furthermore, other
blood samples were taken during CPB to assess the transmyocar-
dial gradient of oxygen content indexed to body surface area
(TMO2; see calculations below), and the transmyocardial gradient
of plasma glucose, lactate (to assess whether myocardial blood
perfusion was adequate), and nitrate (NO2/NO3, index of myocar-
dial NO production). To do so, blood samples were simultaneously
withdrawn upstream in the cardioplegia line and downstream of
the myocardium in the left coronary ostium through a coronary
balloon-tipped, angled soft cannula (Polystan A/S, Vaerløse, Den-
mark) to avoid any possible contamination with blood from the left
ventricle. Blood samples were withdrawn 10 and 30 minutes after
aortic crossclamping. Plasma nitrite and nitrate levels were mea-
sured by using the Griess method, as previously described.18 In
brief, nitrate present in the sample was reduced on nitrite by the
enzyme nitrate reductase, and the total nitrite formed is measured
on the basis of its absorbance at 550 nm.
Continuous Antegrade Blood Cardioplegia
To assess whether differences in transmyocardial oxygen content
and NO release between the esmolol and potassium groups could
be related to the direction of cardioplegic blood flow rather than to
a cardioplegic agent, we measured these parameters in 10 addi-
tional patients receiving cardioplegic solution through the ante-
grade route (potassium group, n  5; esmolol group, n  5). In
brief, after induction of cardiac arrest, the aorta was opened, and
the left and right coronary ostia were cannulated and continuously
perfused through 2 coronary balloon-tipped, angled soft cannulas
at a flow rate of 0.2 L  min1. Doses of potassium and esmolol
were identical to and had the same effects as those described above
for retrograde perfusion. Measurements (oxygen content and NO
concentration) were performed 10 and 30 minutes after aortic
crossclamping in both the cardioplegia line and the self-inflating
double-lumen balloon cannula inserted in the coronary sinus. In-
deed, during antegrade cardioplegia, blood from the coronary sinus
was considered downstream of the myocardium.
Calculations
The transmyocardial gradient for retrograde perfusion is defined as
follows: Plasma concentration (or oxygen content) in the perfusion
line  Plasma concentration (or oxygen content) in the left coro-
nary ostium.
The transmyocardial gradient for antegrade perfusion is defined
as follows: Plasma concentration (or oxygen content) in the per-
fusion line  Plasma concentration (or oxygen content) in the
coronary sinus.
Oxygen content is defined as follows: 1.39  Oxygen satura-
tion  Hemoglobin concentration  0.0031  Blood oxygen
pressure.
Statistics
Data are presented as means  SD. Comparisons were performed
by using the unpaired Student t test or 2-way analysis of variance
for one grouping factor (potassium vs esmolol) and one within
factor (time) when appropriate.
Results
Our study included patients with severe aortic stenosis with
a high LV mass index and a high transaortic mean gradient
(Table 1). Preoperative measurements and aortic cross-
clamping and CPB times were similar in the esmolol and
potassium groups.
Table 2 shows that parameters measured in the retro-
grade perfusion line, namely oxygen content, plasma glu-
cose concentration, and lactate concentration, were similar
in the potassium and esmolol groups at 10 and 30 minutes
after aortic crossclamping. Figure 1 shows that TMO2 was
lower in the esmolol group than in the potassium group
during the entire observational period and that TMO2 in-
creased in all patients, regardless of the cardioplegic agent
used, during aortic crossclamping (P  .001). However, the
transmyocardial gradients of lactate and glucose were un-
changed and in the low physiologic levels in both groups
(Table 2). Accordingly, our data show that myocardial
oxygen consumption was consistently less in the esmolol
than in the potassium group, with no signs of inadequate
oxygen use.
TABLE 2. Comparison of myocardial metabolic data and parameters measured in the retrograde perfusion line between the
potassium and esmolol groups during retrograde cardioplegia
ACC  10 min ACC  30 min
K group ES group K group ES group
Cardioplegic roller-pump flow rate (L  min1) 0.26 0.03 0.25 0.03 0.27 0.03 0.26 0.03
Cardioplegic oxygen content (mL of oxygen  L1) 120 28 120 25 129 22 118 25
Cardioplegic glucose content (mmol  L1) 6.6 1.7 6.5 1.1 7.2 1.0 6.7 1.2
Transmyocardial glucose gradient (mmol  L1) 0.4 0.2 0.6 0.6 0.5 0.3 0.3 0.2
Cardioplegic lactate content (mmol  L1) 1.45 0.37 1.67 0.55 1.55 0.35 1.69 0.53
Transmyocardial lactate gradient (mmol  L1) 0.17 0.22 0.16 0.25 0.16 0.27 0.22 0.30
Measurements were performed 10 and 30 minutes after aortic crossclamping. TMO2 is shown in Figure 1. K, Potassium; ES, esmolol; ACC, aortic
crossclamping.
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Our study further compared the transmyocardial gradient
of NO release during aortic crossclamping time between the
potassium group (n  10) and the esmolol group (n  8)
during retrograde cardioplegia. Figure 2 shows that
transmyocardial gradient of NO release decreased in the
esmolol group during aortic crossclamping, whereas it re-
mained stable in the potassium group.
TMO2 and transmyocardial NO release were also mea-
sured in 10 additional patients (potassium group, n  5;
esmolol group, n  5) during continuous normothermic
antegrade cardioplegia. Figure 1 shows that the TMO2 was
much lower in antegrade cardioplegia in all patients than in
retrograde cardioplegia and that the TMO2 remained lower
in the esmolol group than in the potassium group during
antegrade cardioplegia compared with during retrograde
cardioplegia. Surprisingly, we found a much lower
transmyocardial gradient of NO release in all 10 patients in
antegrade compared with retrograde cardioplegia, with no
difference between the potassium and esmolol groups (Fig-
ure 2). The transmyocardial gradient of glucose (esmolol
group, 0.3  0.1 mmol  L1; potassium group, 0.6  0.5
mmol  L1; both after 30 minutes of aortic crossclamp-
ing) and lactate (esmolol group, 0.10  0.24 mmol  L1;
potassium group 0.35  0.94 mmol  L1; both after 30
minutes of aortic crossclamping) were unaltered by ante-
grade cardioplegia.
Hemodynamic and biologic parameters were recorded 4
hours after the operation and compared with those recorded
preoperatively in the 41 patients who received retrograde
cardioplegia (Table 3). Cardiac index, plasma troponin I
level, and plasma lactate level increased in a similar manner
in the postoperative period in the 2 groups (P  .01 for all).
Figure 1. Individual data of transmyocardial oxygen content indexed to LV mass (TMO2) in the potassium (K) and
esmolol (ES) groups during retrograde (potassium group, n  18; esmolol group, n  23) or antegrade (potassium
group, n  5; esmolol group, n  5) coronary perfusion. These measurements were repeated 10 and 30 minutes
after aortic crossclamping. In addition, an increase in transmyocardial oxygen content indexed to LV mass was
observed during aortic crossclamping in all patients regardless of the cardioplegic agent used or the direction of
cardioplegic blood perfusion (P < .001).
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A similar number of patients received catecholamines,
mostly dobutamine, in the post-CPB period in both groups
(esmolol group, 7/23; potassium group, 8/18). In addition,
plasma troponin I levels at 24 hours after the operation
(potassium group, 4.7  2.9 g  L1; esmolol group,
6.4 3.0 g L1), ventilation time (esmolol group, 13
17 hours [median, 6 hours]; potassium group, 9  5 hours
[median, 7 hours]) and length of stay in the intensive care
unit (esmolol group, 3.3 1.8 days; potassium group, 3.5
1.7 days) were similar in both groups. LV ejection fraction
measured by means of echocardiography 5 days after the
operation was also similar in the esmolol and potassium
groups (59%  19% and 62%  11%, respectively) and
unchanged compared with preoperative values. The mortal-
ity rate was 0% at 3 months.
Discussion
Esmolol has been described as an effective cardioprotective
agent in a few human studies, mostly involving patients
operated on for coronary bypass surgery.6,7 Thus, continu-
ous coronary perfusion with warm esmolol-enriched blood
has been shown to minimize anaerobic metabolism and
myocardial edema formation. We also showed, in the
present study, that esmolol could be an effective cardiopro-
tective agent in hypertrophied human ventricles despite a
high myocardial oxygen consumption19 and an altered de-
livery of oxygen and other energy substrates to cardiac
myocytes, mostly because of reduced capillary density, in-
creased collagen content, or both.20 In addition, although
continuous retrograde blood cardioplegia has been claimed
to provide sufficient oxygen and energy substrates for aer-
obic myocardial metabolism,21 its protective abilities are
still debated.22 Our data strongly suggest that the combina-
tion of esmolol and continuous retrograde blood cardiople-
gia offers an optimal cardioprotective method for aortic
valve replacement.
Our study showed that esmolol administered during aor-
tic crossclamping markedly reduced TMO2 compared with
potassium in all patients, regardless of the direction (ante-
grade or retrograde) of myocardial perfusion flow. This
Figure 2. Comparison of transmyocardial NO release in the potassium (K) and esmolol (ES) groups during retrograde
(potassium group, n  10; esmolol group, n  8) or antegrade (potassium group, n  5; esmolol group, n  5)
cardioplegic perfusion. These measurements were repeated 10 and 30 minutes after aortic crossclamping. P values
represent differences between the potassium and esmolol groups; there was no effect of time.
TABLE 3. Comparison of hemodynamic and biologic parameters between preoperative and postoperative periods in the
potassium and esmolol groups
Preoperative Postoperative (4 h)
K group ES group K group ES group
Cardiac index (L  min1  m2) 2.1 0.6 2.3 0.8 2.8 0.5* 2.7 0.7*
Mixed pulmonary artery oxygen saturation (%) 73 8 74 7 73 6 72 7
Mean PAP (mm Hg) 27 9 23 6 25 7 24 5
Troponin I (g  L1) 0.0 0.0 0.2 0.5 4.7 2.7* 4.8 2.3*
Lactate (mmol  L1) 1.1 0.5 1.4 0.4 1.9 1.1* 2.5 1.6*
Creatinine (mol  L1) 88 18 95 33 94 28 94 28
Troponin and lactate represent plasma concentrations. No difference was found between the K and ES groups for any measured parameter. K, Potassium;
ES, esmolol; PAP, pulmonary arterial pressure.
*P  .01 versus the same group at the preoperative period.
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implies that myocardial oxygen consumption (TMO2 
cardioplegia blood flow) was lower with esmolol than with
potassium. This was unexpected. Indeed, because heart con-
tractile activity accounts for 70% to 80% of myocardial
oxygen consumption,23 we expected that heart contraction
in the esmolol group, although minimal, would have in-
creased myocardial oxygen consumption to a greater level
than that of the unbeating heart in the potassium group. Our
data also showed that esmolol-induced low myocardial ox-
ygen consumption was not related to oxygen misconsump-
tion because neither the transmyocardial gradient of lactate
nor that of glucose was altered in the esmolol group com-
pared with that in the potassium group at any time. This was
confirmed by similar levels of the global marker of myo-
cardial ischemia, plasma troponine I, in both groups at all
measured times. Mechanism of the difference in myocardial
oxygen consumption between the esmolol and potassium
groups remains to be elucidated. Indeed, hyperkalemic car-
dioplegic solutions induce a depolarization of membrane
resting potential and an inactivation of fast Na channels
that result in diastolic cardiac arrest.24 However, it also
causes Ca2 influx into cardiac myocyte and cardiac endo-
thelial cells,25 which results in increasing myocardial oxy-
gen consumption. By contrast, esmolol, as with other
-blockers, is known to decrease myocardial oxygen con-
sumption and ultimately to improve oxygen use in human
patients.8,15
Our study also showed a lower TMO2 in continuous
antegrade cardioplegia compared with that in continuous
retrograde blood cardioplegia. This difference is likely ex-
plained by the different percentage of nutritive flow deliv-
ered to the myocardium with these 2 techniques. Indeed,
although the nutritive flow to the myocardium per se is
almost 100% of the cardioplegic perfusion in continuous
antegrade cardioplegia, it ranges from 30% to 70% in con-
tinuous retrograde cardioplegia.26,27 In the latter, cardiople-
gic perfusion is partly bypassing the myocardial capillary
bed, going directly to the right ventricular or LV cavities
through the thebesian veins.
Our study also demonstrated an important transmyocar-
dial gradient of NO release a couple of minutes after the
shift of cardioplegia flow direction from antegrade to retro-
grade in all patients, regardless of the cardioplegic agent
used. These data favor endothelial cells as a potential source
of NO release rather than cardiac myocytes. Indeed, in our
study sudden changes in flow-derived mechanical stresses
and the biochemical environment in coronary endothelium
after the change of cardioplegic blood flow direction from
antegrade to retrograde might have increased endothelial
NO release, as previously described.28,29 These sudden al-
terations, compared with physiologic conditions, include
blood flow direction at the opposite direction of the physi-
ologic alignment of the endothelial cell layer, an increase in
coronary venous pressure from a couple of millimeters of
mercury in physiologic conditions to 30 to 40 mm Hg
during cardioplegia, and a sudden increase in oxygen ten-
sion in coronary veins at levels present in the arteries. Our
study further showed that potassium induced a sustained
NO release during aortic crossclamping, whereas NO re-
lease decreased with esmolol during retrograde cardiople-
gia. Indeed, a high potassium concentration is known to
increase the intracellular Ca2 concentration (see above),
which might stimulate the calcium-dependent constitutive
isoforms of NO synthase, especially NO synthase 3, in
endothelial cells. Although the clinical relevance of the
coronary perfusion-induced NO release is still uncertain,
evidence shows that NO might have potential beneficial
effects on ventricular relaxation, coronary circulation, or
both, especially in ischemic and hypertrophied human ven-
tricles,20 but also deleterious effects if transformed to the
toxic oxidant peroxynitrite.30
In summary, our study showed that esmolol can be safely
used as a continuous retrograde protective agent in the
hypertrophied human heart. Furthermore, esmolol markedly
decreased myocardial oxygen consumption compared with
potassium, with no signs of myocardial insult. In addition,
our study showed a much greater NO production with
retrograde than antegrade cardioplegia, regardless of the
agent used.
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Discussion
Dr Tomas A. Salerno (Miami, Fla). Ideal myocardial protection
requires the infusion of cardioplegia, antegrade and retrograde,
either alternating, as shown by Buckberg, or simultaneously, as
shown by Buckberg and our group. Furthermore, Roxanne Deslau-
riers from our group showed that retrograde cardioplegia in pigs
does not provide uniform myocardial distribution of flow. This
might explain your results.
I have a couple of questions for you. First, how long was your
crossclamp time, and did you refuse antegrade cardioplegia?
Second, in those hearts did you measure and did you have an
opportunity to do myocardial biopsies to measure the energetics of
the heart, microscopy, cellular edema, and other factors?
Your article is an important contribution. I have come all the
way from eliminating potassium from cardioplegia, but I have not
used esmolol.
Dr Scorsin. Thank you, Dr Salerno, for your kind remarks. Our
crossclamp time was around 60 minutes.
Your second question was whether we have done biopsies or
other measurements. No, we made only those measurements I
showed you.
Dr Salerno. Did you refuse antegrade or retrograde cardiople-
gia?
Dr Scorsin. In this protocol, no. It was always continuous
retrograde or antegrade cardioplegia.
Dr Uwe Mehlhorn (Cologne, Germany). I have 2 questions.
First, did you always achieve complete cardiac arrest with your
initial dose of esmolol? Second, what about your reperfusion times
on pump? As you know, esmolol has a half-life of about 7 to 9
minutes, and it needs quite a while to be metabolized. What
inotropic doses did you need?
Dr Scorsin. Those are good questions. We did not achieve
complete arrest of the heart but minimal myocardial contraction
with esmolol. So we can see that it is a very depressed myocar-
dium. In this study there is no difference in bypass time after
clamping the aorta, but after that, we have been using bypass for
all kinds of patients, and we observed that sometimes we need
more time to stop the CPB because the heart remained depressed
with esmolol. In those patients we infuse a little bit of dobutamine
to stimulate -adrenergic receptors, and we can quickly stop CPB.
Dr Sidney Levitsky (Boston, Mass). This is a very interesting
article because investigators have toyed with -blockers for a long
period of time. One of the advantages of something like esmolol is
that it decreases the myocardial oxygen consumption very rapidly.
As you know, the secret is the first 6 seconds, when the heart, after
aortic crossclamping, goes from aerobic to anaerobic metabolism.
The other advantage I think you have with the -blocker is that
potassium increases the cytosolic calcium within the cell, and I do
not know what happens when you use something like esmolol or
a -blocker.
As far as you know, has anyone measured cytosolic calcium
during a -blocker or continuous -blocker type of myocardial
protection? As you know, the only purpose of using potassium is
really to stop the heart from wiggling. In the past we have used,
with the Quest System, just potassium and whole blood. That
works well on a continuous basis, but if you want to do mitral
valve surgery and coronary surgery you are not going to be able to
use continuous infusion, unless you want to have a bloody field. I
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wonder whether this method will work as well under those cir-
cumstances.
I am sure you have done it, and you will probably have the
answer, but it is very clever, and for aortic valve replacements with
short crossclamp times, I think this might be a very valid method.
Dr Scorsin. As to the first question, I have no idea exactly.
Nobody knows exactly how -blockers work, but I am sure that
calcium is one of the main issues involved in oxygen consumption.
About how to perfuse the heart, obviously it seems that the
antegrade way is better. However, in these patients there were no
coronary lesions. For patients undergoing coronary bypass, we
must perfuse in a retrograde manner, and from time to time, as Dr
Salerno said, it is better to give 2 or 3 minutes of antegrade
perfusion.
Dr Frank W. Sellke (Boston, Mass). Your NO data are a little
confusing to me. You are saying that esmolol increases endothelial
preservation, yet NO release with esmolol is less. NO release is a
very poor indicator of endothelial function, but if you were to use
it, I would think that you would make the opposite conclusion.
Dr Scorsin. I will try to explain it better. The only difference
that we could draw from the present study is that what induced NO
is the direction of flow and of shear stress. Endothelial cells are
aligned according to the direction of flow. When you change the
direction of flow or when you change pressure or even oxygen
content, you can stimulate endothelial cells to produce NO. That
was the difference we saw between the antegrade group and the
retrograde group.
Dr Sellke. Maintaining NO production is not necessarily—.
Dr Scorsin. It is a bad or a good thing? Nobody knows.
Dr Sellke. Well, it is debatable. There is some evidence that
NO can help myocardial protection, but I do not think you should
be using it as an indicator of endothelial dysfunction or injury.
Your title says preserving myocardial metabolism and endothelial
function. That is why I ask.
Dr Scorsin. Yes, because if NO is produced, maybe it is by
inducible NO synthase.
Dr Sellke. Well, this is pretty early. I do not think so.
Dr Spotnitz. Let’s stop right here. You gentlemen can discuss
this privately. Dr Lazar or Dr Buckberg, do you have any com-
ments?
Dr Gerald D. Buckberg (Los Angeles, Calif). Well, I am not
sure what the NO data mean, but it is an interesting observation.
Conceivably what you are seeing is that with retrograde flow that
is continuous, you are really perfusing the same area all the time.
Normally the heart contracts and relaxes, and that gives a distri-
bution of flow, and maybe what you are seeing with the esmolol is
that a small amount of contraction is providing flow to adjacent
muscle, and you are seeing a more normal endothelial perfusion
with that. Maybe the high NO might reflect the fact you have
uneven flow, but it is recoverable. When you get back to normal
perfusion you are seeing NO being produced to restore the endo-
thelium. That might be one explanation for what you are seeing.
The results were the same.
The other thing is that you are kind of looking at one thing or
another, potassium or calcium blockage, and I think protection is
not just one thing or the other. I think you have to combine many
things. As Dr Salerno says, not only do you have to look at the way
you are giving it, but you have to deal with many things when you
are doing it. Therefore, you add many other parts to the cardiople-
gic solution. I do not think any method of protection with a single
agent is going to be as good as a combination of things. As we
learn more about the combination, I think our cardioplegic solu-
tions will get better at protecting different areas.
Dr Bradley S. Allen (Oak Lawn, Ill). Let’s talk a little bit about
a different scenario and see what you think. Is it possible that the
potassium is perfusing areas of the heart that because the NO is
high the esmolol is not getting to? In other words, maybe it is
getting to the subendocardium, and the NO is good; it is allowing
the potassium to perfuse other areas, and that is why your oxygen
content is a little higher because you are perfusing areas that
otherwise would not be perfused.
I am curious when you talk about whether it is good or bad. Did
you measure pressures in the cardioplegic solution? If the NO was
good, then I would expect the pressure to be lower, and if the NO
was bad and causing vascular endothelial damage, I expect those
vessels to be edematous and not working. Therefore, the perfusion
pressure, especially with antegrade cardioplegia, would be higher.
Could you comment?
Dr Scorsin. These data are very difficult to understand. We
opened the door, and therefore now we must understand what it
means and follow with other studies.
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